BOSTON--(BUSINESS WIRE)--Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced $153M Series B funding led by Kinnevik, with new investors Regeneron Ventures, ICONIQ ...
Drugs made of mRNA have the potential to transform medicine—if only they could get into cells in one piece. Now, University ...
Researchers shamelessly copy viral strategies to get mRNA medicines into cells in one piece (Illustration courtesy of Joe Luciani ...
-- Financing oversubscribed; proceeds from the round will be used to expand Strand’s growing mRNA platforms into multiple immuno-oncology and disease settings, and advance lead drug into Phase 1 ...
Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced that Jake Becraft, PhD, Co-founder and Chief Executive Officer, will present at the 44th Annual J.P. Morgan ...
Leader in mRNA therapeutics strengthens clinical development expertise with globally recognized oncology innovator Strand Therapeutics, the leader in programmable mRNA medicines, today announced the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Boston biotech that was born ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results